Erectile dysfunction: does insulin resistance play a part?

Fertility and Sterility

Volumn 88, Issue 4, 2007, Pages 771-778

  Trussell, J C ^a   Legro, Richard S ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Erectile dysfunction; insulin resistance; metformin; nitric oxide

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; PROTEIN KINASE B; SEX HORMONE; SILDENAFIL; TADALAFIL; VARDENAFIL;

ALGORITHM; CHROMOSOME; CORRELATION ANALYSIS; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; MEDLINE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASODILATATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANIMALS; GONADAL STEROID HORMONES; HUMANS; IMPOTENCE; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 34848892725     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.01.116     Document Type: Review

References (72)

1. Laumann E.O., Paik A., and Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281 (1999) 537-544
2. Litwin M.S., Nied R.J., and Dhanani N. Health related quality of life in men with erectile dysfunction. J Gen Intern Med 13 (1998) 159-166
3. Gonzolez-Cadavid N.F., and Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 39 (2004) 1705-1712
4. Esposito K., Giugliano F., Martedi E., Giovanni F., Marfella R., D'Armiento M., et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 28 (2005) 1201-1203
5. Blumentals W.A., Gomez-Caminero, Joo S., and Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction?. Int J Impot Res 16 (2004) 350-353
6. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: finding from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
7. Makhsida N., Shah J., Yan G., Fisch H., and Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834
8. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 187 (2002) 356-359
9. Wheatcroft S.B., Williams I.L., Shah A.M., and Kearney M.T. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetes 20 (2003) 255-268
10. Petrie J.R., Shinichiro U., Webb D.J., Elliott H.L., and Connell J.M. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93 (1996) 1331-1333
11. NIH Consensus Conference. Impotence. NIH Consensus Conference Development Panel on Impotence. JAMA 270 (1993) 83-90
12. Nehra A., Steers W.D., Althof S.E., Andersson K.E., Burnett II A.L., Costabile R.A., et al. Third International Conference on the Management of Erectile Dysfunction: linking pathophysiology and therapeutic response. J Urol 170 (2003) 53-55
13. Seftel A.D. Erectile dysfunction in the elderly. Epidemiology, etiology, and approaches to treatment. J Urol 169 (2003) 1999-2007
14. Siroky M.B. Azadzoi. Vasculogenic erectile dysfunction: newer therapeutic strategies. J Urol 170 (2003) S24-S30
15. Barouch L.A., Harrison R.W., Skaf M.W., Rosas G.O., Cappola T.P., Kobeissi Z.A., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthetase isoforms. Nature 416 (2002) 337-339
16. Montorsi F., Griganti A., Salonia A., Rigatti P., and Burnett A.L. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 45 (2004) 123-133
17. Ignarro L.J., Bush P.A., Buga G.M., Wood K.S., Fukuto J.M., and Fajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170 (1990) 843-850
18. Rajfer J., Aronson W.J., Bush P.A., Dorey F.J., and Ignarro L.J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326 (1992) 90-94
19. Cook S., and Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs. Fundam Clin Pharmacol 16 (2002) 441-453
20. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101 (2000) 676-681
21. Zeng G., and Quon M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98 (1996) 894-898
22. Katakam P.V., Ujhelyi M.R., Hoenig M., and Miller A.W. Metformin improves vascular function in insulin-resistant rats. Hypertension 35 (2000) 108-112
23. Mather K.J., Berma S., and Anderson T.J. Improved endothelial function with metformin in type II diabetes mellitus. J Am Coll Cardiol 37 (2001) 1344-1350
24. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646
25. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
26. Jiang Z.Y., Lin Y.W., Clemont A., Feener E.P., Hein K.D., Igarashi M., et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker rats. J Clin Invest 104 (1999) 447-457
27. Hurt K.J., Musicki B., Palese M.A., Crone J.K., Becker R.E., Moriarity J.L., et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 99 (2002) 4061-4066
28. Zembowicz A., Tang J., and Wu K. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidyl choline. J Biol Chem 270 (1995) 17006-17010
29. Awolesi M., Sessa W.C., and Sumpio B. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. J Clin Invest 96 (1995) 1449-1454
30. Sessa W.C., Pritchard K., Seyedi N., Wang J., and Hintze T.H. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide gene expression. Circ Res 74 (1994) 349-353
31. Bouloumie A., Schinikerth V., and Bussed R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41 (1999) 773-780
32. Hirata K., Miki N., Kuroda Y., Sakoda T., Kawashima S., and Yokoyama M. Low concentrations of oxidized low-density lipoprotein and lysophosphatidyl choline up-regulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 76 (1995) 958-962
33. Nishida K., Harrison D.G., Navas J., Fisher A., Dockery S., Uematsu M., et al. Molecular cloning and characterization of the constitutive bovine endothelial cell nitric oxide synthase. J Clin Invest 90 (1992) 2092-2096
34. McQuillan L., Leung G.K., Marsden P.A., Kostyk S., and Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and post-transcriptional mechanisms. [correction in Am J Physiol Heart Circ Physiol 1995;268:1-a]. Am J Physiol Heart Circ Phys 267 (1994) H1921-H1927
35. Laufs U., La Fata V., Plutzky J., and Liao J. Upregulation of endothelial nitric oxide synthase by HMB CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
36. Jesmin S., Sakuma I., Salah-eldin A., Nonomura K., Hattori Y., and Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 31 (2003) 401-418
37. Nawras M., Shah J., Yan G., Fisch H., and Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834
38. Carey D.G., Jenkins A.B., Campbell L.V., Freund J., and Chisholm D.J. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45 (1996) 633-638
39. Scherrer U., and Sartori C. Insulin as a vascular and sympathoexcitatory hormone. Implications for blood pressure, insulin sensitivity and cardiovascular morbidity. Circulation 96 (1997) 4104-4113
40. Sartori C., and Scherrer U. Insulin as a vasoactive hormone. At the crossroad of metabolic and cardiovascular regulation. J Hypertens 17 (1999) 1517-1525
41. Scherrer U., and Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity, and cardiovascular morbidity. Eur J Endocrinol 142 (2000) 315-323
42. Laakso M., Edelman S.V., Brechtel G., and Baron A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41 (1992) 1076-1083
43. Akingba A.G., and Burnett A.L. Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diabetic rat. Mol Urol 5 (2001) 189-197
44. Cellek S., Rodrigo J., Lobos E., Fernandez P., Serrano J., and Moncada S. Selective nitrenergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. Br J Pharmacol 128 (1999) 1804-1812
45. Saenz de Tejada I., Goldstein I., Azadzoi K.M., Drand R.J., and Gohen R.A. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320 (1989) 1025-1030
46. Azadzoi K.M., and Saenz de Tejada I. Diabetes mellitus impairs neurogenic and endothelium-mediated relaxation of rabbit corpus cavernosum smooth muscle. J Urol 148 (1992) 1587-1591
47. Papapetropoulos A., Garcia-Cardena G., Madri J.A., and Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100 (1997) 3131-3139
48. Gnduz M.I., Gumus B.H., and Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. Asian J Androl 6 (2004) 355-358
49. Kim S.C. Hyperlipidemia and erectile dysfunction. Asian J Androl 2 (2000) 161-166
50. Shoji M. Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci 66 (2000) 2557-2562
51. Saltzman E.A., Guay A.T., and Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 171 (2004) 255-258
52. Tchernof A., Labrie F., Belanger A., and Despres J.P. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J Endocrinol 150 Suppl (1996) S155-S164
53. Seidell J.C., Bjorntorp P., Sjostrom L., Kvkist H., and Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels but negatively with testosterone levels. Metabolism 39 (1990) 897-901
54. Leenen R., van der Kooy K., Seidell J.C., Deurenberg P., and Koppeschaar H.P. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 78 (1994) 1515-1520
55. Kaukua J., Pekkarinen T., Sane T., and Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obes Res 11 (2003) 689-694
56. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuorainene T.P., Salonen R., et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149 (2003) 601-608
57. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonene K., Tuorainen T.P., Volkonen V.P., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 (2004) 1036-1041
58. Holmang A., and Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 146 (1992) 505-510
59. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
60. Keene L.C., and Davies P.H. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 18 (1999) 5-25
61. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 100 (2003) 215-234
62. Cleophas T.J., vd Mey N., Meulen J., and Niemeyer M.G. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Am J Ther 4 (1997) 117-122
63. Rosen R., Riley A., Wagner G., Osterlich I., Kilpatrick J., and Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
64. Hanson-Divers C., Jackson S., Lue T., Crawford S., and Rosen R. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 159 (1998) 1541-1547
65. Guay A.T., Spark R.F., Bansal S., Cunningham G.R., Goodman N.F., Nankin H.R., et al., American Association of Clinical Endocrinologists Male Sexual Dysfunction Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem-2003 update. Endocr Pract 9 (2003) 77-95
66. The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. Int J Impot Res 11 (1999) 59-74
67. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Ladim J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
68. Lindstrom J., Louheranta A., Mannelin M., Rastas M., Salminen V., Eriksson J., et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26 (2003) 3230-3236
69. Giuliano F.A., Leriche A., Jaudinot E.O., and de Gendre A.S. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 64 (2004) 1196-1201
70. Ferrannini E., Hafner S.M., Mitchell B.D., and Stern M.P. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34 (1991) 416-418
71. Kaiser D.R., Billups K., Mason C., Wetterling R., Lundberg J.L., and Bank A.J. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43 (2004) 179-184
72. Bacon C.G., Murray A.M., Kawachi I., Giovannucci E., Glasser D.B., and Rimm E.B. A prospective study of risk factors for erectile dysfunction. J Urol 176 (2006) 217-221